SARS-CoV-2 RBD of Spike protein, K417T, E484K, N501Y – lineage B.1.1.28.1 – BR Gamma Variant

Reference:
Product nameSARS-CoV-2 RBD of Spike protein, K417T, E484K, N501Y – lineage B.1.1.28.1 - BR Gamma Variant
Origin speciesSARS-COV2
Expression systemEukaryotic expression
Sequence  YP_009724390.1
Molecular weight35kDa
BufferPBS, pH7.5
Delivery conditionDry Ice
Storage condition4°C for short term; -20°c or -80°C for long term
BrandProteoGenix
Host speciesMammalian cells
ApplicationsELISA,WB,,,
Fragment TypeSpike protein fragment
Aliases /SynonymsP.1 lineage; 484K.V2; Brazilian Variant; BR Variant; lineage B.1.1.28.1; Gamma variant
ReferencePX-COV-P054
Related ProductsAnti-RBD-5 antibody (Imdevimab),Anti-2019-nCoV(S1)-3 antibody
PublicationsWinklmeier, S. et al. Persistence of functional memory B cells recognizing SARS-CoV-2 variants despite loss of specific IgG. medRxiv 2021.05.15.21257210. doi: 10.1101/2021.05.15.21257210
NoteFor research use only. Not suitable for in vitro diagnostic and human use.

General information on SARS-CoV-2 RBD of Spike protein, P.1, K417T, E484K, N501Y – 484K.V2 – BR Variant

A new emerging variant of SARS-CoV-2 was detected in December 2020 in Manaus (Amazonas state, Brazil). The variant belongs to a new lineage of the virus – lineage P.1, which, according to genomic analysis, descends from an earlier Brazilian variant – B.1.1.28 (detected in March 2020). The P.1 lineage carries several mutations with biological importance like the K417T, E484K, and N501Y amino acid changes on the spike. The latter had been previously identified in two other variants of the virus responsible for the COVID-19 disease, namely B.1.1.7 and B.1.351, which originated in the UK and South Africa, respectively. The N501Y change occurs in a key residue of the receptor-binding domain (RBD) of the spike, known to interact directly with its human ligand – ACE2 (angiotensin-converting enzyme 2). Preliminary analysis revealed this mutation might enhance virus transmissibility, with unknowable consequences for mortality and morbidity rates.
The new lineage also shares an E484K mutation with the South African variant. This modification is expected to increase transmissibility and help the virus evade neutralizing immune responses. Moreover, the two emerging variants carry a mutation on position 417. But while the South African variant harbors the K417N mutation, the new variant carries a K417T change. Preliminary studies reveal that position K417 is an important target of neutralizing antibodies, suggesting that both mutations may help the virus evade vaccine-mediated and naturally acquired immunity. The set of mutations/deletions shared between the three lineages seem to have arisen independently (convergent evolution) and to spread rapidly. Current data suggests that researchers, clinicians, and policymakers should redouble virus tracking efforts and further investigate the biological consequences of these mutations.
Enhanced transmissibility is currently supported by the fast spread of this variant in Brazil, Japan, United Kingdom, among other countries. At the time of writing (January 18, 2021), over 100 genomes of the new lineage have been reported in Brazil alone, representing an abundance of 21%. In total, the new lineage P.1 carries 17 unique amino acid changes, 3 deletions, and 4 synonymous mutations.

SDS-PAGE for SARS-CoV-2 RBD of Spike protein, K417T, E484K, N501Y – lineage B.1.1.28.1 - BR Gamma Variant

SARS-CoV-2 RBD of Spike protein, K417T, E484K, N501Y – lineage B.1.1.28.1 - BR Gamma Variant, on SDS-PAGE under non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Publication

Winklmeier, S. et al. Persistence of functional memory B cells recognizing SARS-CoV-2 variants despite loss of specific IgG. medRxiv 2021.05.15.21257210. doi: 10.1101/2021.05.15.21257210

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “SARS-CoV-2 RBD of Spike protein, K417T, E484K, N501Y – lineage B.1.1.28.1 – BR Gamma Variant”

Your email address will not be published. Required fields are marked *

Related products

Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1031 400€
Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1032 400€
Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1033 300€
Sotrovimab  Biosimilar – Anti-Spike glycoprotein mAb – Research Grade
Biosimilar Sotrovimab Biosimilar – Anti-Spike glycoprotein mAb – Research Grade PX-TA1637 400€
Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb – Research Grade
Biosimilar Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb – Research Grade PX-TA1750 400€
Beludavimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Beludavimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1797 400€
Upanovimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Upanovimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1798 400€
Amubarvimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Amubarvimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1799 400€
Romlusevimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Romlusevimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1800 400€
Anti-RBD-4 antibody (Casirivimab)
Biosimilar Anti-RBD-4 antibody (Casirivimab) PTXCOV-A552 300€
Anti-RBD-5 antibody (Imdevimab)
Biosimilar Anti-RBD-5 antibody (Imdevimab) PTXCOV-A553 300€
Stable Isotope Labeled Anti-RBD-4 antibody (Casirivimab)
SIL Stable Isotope Labeled Anti-RBD-4 antibody (Casirivimab) PTXCOV-A552-SIL 1500€
Anti-2019-nCoV(S1) – 2 (H4) antibody
Monoclonal Antibody Anti-2019-nCoV(S1) – 2 (H4) antibody PTXCOV-A514 300€
Anti-2019-nCoV(S1)-1 IgM antibody
Monoclonal Antibody Anti-2019-nCoV(S1)-1 IgM antibody PTXCOV-A542 380€
ACE2 protein – Soluble ectodomain of human ACE-2 (aa 1-740)
Receptor ACE2 protein – Soluble ectodomain of human ACE-2 (aa 1-740) PX-COV-P048 185€

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.